Filing Details
- Accession Number:
- 0001209191-18-057429
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-06 17:00:47
- Reporting Period:
- 2018-11-02
- Accepted Time:
- 2018-11-06 17:00:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1581280 | Twist Bioscience Corp | TWST | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1219039 | Keith Crandell | 8755 W. Higgins Road, Suite 1025 Chicago IL 60631 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-11-02 | 1,182,645 | $0.00 | 1,182,645 | No | 4 | C | Indirect | See footnotes |
Common Stock | Acquisiton | 2018-11-02 | 718,275 | $0.00 | 1,900,920 | No | 4 | C | Indirect | See footnotes |
Common Stock | Acquisiton | 2018-11-02 | 266,776 | $0.00 | 2,167,696 | No | 4 | C | Indirect | See footnotes |
Common Stock | Acquisiton | 2018-11-02 | 224,726 | $0.00 | 2,392,422 | No | 4 | C | Indirect | See footnotes |
Common Stock | Acquisiton | 2018-11-02 | 15,000 | $14.00 | 2,407,422 | No | 4 | P | Indirect | See footnotes |
Common Stock | Acquisiton | 2018-11-02 | 894,146 | $0.00 | 894,146 | No | 4 | C | Indirect | See footnotes |
Common Stock | Acquisiton | 2018-11-02 | 60,000 | $14.00 | 954,146 | No | 4 | P | Indirect | See footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnotes |
No | 4 | C | Indirect | See footnotes |
No | 4 | C | Indirect | See footnotes |
No | 4 | C | Indirect | See footnotes |
No | 4 | P | Indirect | See footnotes |
No | 4 | C | Indirect | See footnotes |
No | 4 | P | Indirect | See footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2018-11-02 | 1,182,645 | $0.00 | 1,182,645 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2018-11-02 | 718,275 | $0.00 | 718,275 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2018-11-02 | 266,776 | $0.00 | 266,776 | $0.00 |
Common Stock | Series D Preferred Stock | Disposition | 2018-11-02 | 224,726 | $0.00 | 224,726 | $0.00 |
Common Stock | Series D Preferred Stock | Disposition | 2018-11-02 | 894,146 | $0.00 | 894,146 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 0 | Direct |
Footnotes
- Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
- The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- Keith Crandell is a managing director of ARCH VII LLC and AVP GPLLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- Reflects shares purchased in the Issuer's initial public offering.
- The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- The expiration date is not relevant to the conversion of these securities.